Sanofi ADR (SNY)

47.07
-0.62(-1.30%)
After Hours
47.07
0.00(0.00%)
- Real-time Data
  • Volume:
    1,940,980
  • Bid/Ask:
    47.00/47.51
  • Day's Range:
    46.92 - 47.53

SNY Overview

Prev. Close
47.69
Day's Range
46.92-47.53
Revenue
64.8B
Open
47.44
52 wk Range
45.17-54.26
EPS
2.78
Volume
1,940,980
Market Cap
118.99B
Dividend (Yield)
1.81
(4.04%)
Average Vol. (3m)
1,765,531
P/E Ratio
17.16
Beta
0.59
1-Year Change
-6.07%
Shares Outstanding
1,255,273,146
Next Earnings Date
Feb 04, 2022
What is your sentiment on Sanofi ADR?
or
Market is currently closed. Voting is open during market hours.

  • Credit Suisse Stick to Their Buy Rating for Sanofi
    • ByInvesting.com-

    Credit Suisse (SIX:CSGN) analyst Dominic Lunn maintained a Buy rating on Sanofi (NASDAQ:SNY) on Wednesday, setting a price target of EUR96, which is approximately 13.32% above...

  • UBS Stick to Their Buy Rating for Sanofi
    • ByInvesting.com-

    UBS analyst Laura Sutcliffe maintained a Buy rating on Sanofi (NASDAQ:SNY) on Thursday, setting a price target of EUR116, which is approximately 36.93% above the present share...

Sanofi ADR Company Profile

Employees
99412

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. It also has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration with TrialSpark Inc. to execute clinical research studies in the areas of chronic obstructive pulmonary disease. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralSellStrong SellStrong SellSell
Technical IndicatorsStrong BuyStrong SellStrong SellStrong SellStrong Sell
SummaryBuyStrong SellStrong SellStrong SellStrong Sell
  • what is going on?why drop 4% inpremarket?
    0
    • don’t know 🤷‍♂️
      0
  • NEWS: Sanofi agrees to make Moderna COVID-19 vaccine in the U.S. starting in September
    0
    • Announcement RIGHT NOW about a +$900 Million investment in Canada
      0
      • sanofi said it's vaccine will be available next year..
        0
        • but they have more products in pipeline...not just the vaccine
          0
      • Whi is it falling? FDA approval end its going down?
        0
        • Next target 52 buy at 48
          0
          • ARPO a small stock has given me 22% rise , that too on a day when all others have disappointed . Nova , Mrna , Bntx , Astra , Sanofi ... Seriously I salute to the guys running ARPO. .. its been so stable when all others are horribly unpredictable. ARPO has hd its base value and maintained its 1.5 level and Now its on 1.83 and after market is up again. highly recommended if someone wants to invest 1000 dollars and forget it for a while , I am sure its worth putting your 💰......
            0
            • https://ca.finance.yahoo.com/news/u-pay-2-1-billion-122206294.html
              0
              • TONIX PHARMACEUTICALS - WILL PRESENT CERTAIN INFORMATION REGARDING ITS VACCINE CANDIDATES TARGETING COVID-19 AT A  panel on may 19
                3
                • come on, you had good news today, why not going up?
                  0
                  • Companies upside looks unbelievable its the next awaiting Gilead. Partnering up with moderna, supporting the coronavirus outbreak with strong balance sheet. Its a must buy.
                    0
                    • President Donald Trump reportedly owns a stake in a company that produces hydroxychloroquine, the anti-malaria drug he has repeatedly touted as a coronavirus treatment even though his experts say there’s no strong evidence it works. 
                      2
                      • Dear Mr. Abbas Otobus., I would like to suggest you without any responsibility my personal investment to invest in Curetis NV and OpGen ., what do you think Sir ?
                        0
                        • Probably will gain too much in next 6 months because of using hydroxychloroquine for covid-19 prophylaxis and treatment
                          0
                          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.